Uniqure NV (NASDAQ:QURE) Short Interest Up 6.2% in June

Share on StockTwits

Uniqure NV (NASDAQ:QURE) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 2,348,400 shares, a growth of 6.2% from the May 15th total of 2,212,100 shares. Based on an average trading volume of 666,900 shares, the days-to-cover ratio is presently 3.5 days. Currently, 11.2% of the shares of the stock are sold short.

In other news, CEO Matthew C. Kapusta sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $77.45, for a total value of $619,600.00. Following the completion of the transaction, the chief executive officer now directly owns 409,407 shares in the company, valued at $31,708,572.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $57.18, for a total transaction of $88,400.28. Following the completion of the transaction, the insider now owns 54,539 shares of the company’s stock, valued at $3,118,540.02. The disclosure for this sale can be found here. Insiders sold 23,546 shares of company stock valued at $1,556,820 over the last 90 days. 2.91% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of the business. FMR LLC increased its stake in shares of Uniqure by 0.8% in the first quarter. FMR LLC now owns 3,688,791 shares of the biotechnology company’s stock worth $220,036,000 after buying an additional 29,629 shares during the period. Pearl River Capital LLC purchased a new position in shares of Uniqure in the first quarter worth $32,000. Harvest Group Wealth Management LLC purchased a new position in shares of Uniqure in the first quarter worth $26,000. Vivo Capital LLC bought a new stake in Uniqure in the first quarter valued at $10,757,000. Finally, Sphera Funds Management LTD. boosted its holdings in Uniqure by 30.9% in the fourth quarter. Sphera Funds Management LTD. now owns 232,849 shares of the biotechnology company’s stock valued at $6,711,000 after acquiring an additional 55,000 shares in the last quarter. 60.10% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts recently weighed in on QURE shares. SunTrust Banks raised their target price on shares of Everbridge to $87.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Zacks Investment Research downgraded shares of Farmland Partners from a “hold” rating to a “sell” rating in a research note on Friday. Robert W. Baird started coverage on shares of Uniqure in a research note on Thursday, March 28th. They issued an “outperform” rating and a $85.00 target price on the stock. Cantor Fitzgerald raised their target price on shares of Cerner from $75.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, July 8th. Finally, Piper Jaffray Companies set a $80.00 target price on shares of Canopy Growth and gave the company a “buy” rating in a research note on Friday, April 12th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Uniqure has an average rating of “Buy” and an average price target of $78.18.

QURE stock opened at $70.32 on Friday. The stock has a market capitalization of $2.66 billion, a P/E ratio of -30.05 and a beta of 1.05. Uniqure has a one year low of $21.98 and a one year high of $82.49. The business’s 50 day simple moving average is $71.87. The company has a debt-to-equity ratio of 0.38, a current ratio of 9.51 and a quick ratio of 9.51.

Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.03). The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. Uniqure had a negative return on equity of 48.90% and a negative net margin of 1,032.06%. As a group, equities analysts forecast that Uniqure will post -3 EPS for the current fiscal year.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Recommended Story: What are municipal bonds?

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.